Core Insights - The company reported a disease control rate of 74.4% for TTFields therapy, significantly higher than the historical control rate of 48% [1][2] - The FDA approved Optune Pax for the treatment of locally advanced pancreatic cancer, marking the first new treatment in nearly 30 years [4] Clinical Trial Results - The PANOVA-4 trial showed a median duration of TTFields therapy of 25.6 weeks, with good tolerability among participants [1] - Secondary endpoints revealed an objective response rate of 34.6% and a median overall survival of 9.7 months, highlighting the potential of TTFields in treating metastatic pancreatic ductal adenocarcinoma [3] Market Performance - The stock is currently trading 4% below its 20-day simple moving average and 2.7% below its 100-day simple moving average, indicating short-term weakness [5] - Over the past 12 months, shares have decreased by 34.03%, and the stock is closer to its 52-week lows than highs [5] Analyst Consensus - The stock carries a Buy Rating with an average price target of $43.95, although it is underperforming the broader market [7] - Recent analyst actions include a Buy rating from HC Wainwright & Co. with a target raised to $49.00, while Wedbush maintains a Neutral rating with a target of $18.00 [8] Technical Indicators - The RSI is at 42.63, indicating neutral territory, while the MACD shows a value of -0.2151, suggesting bearish pressure on the stock [5][6] - The combination of neutral RSI and bearish MACD indicates mixed momentum for the stock [6]